Zanidatamab is a bispecific antibody that binds to 2 non-overlapping extracellular epitopes of the HER2 receptor.

The apoptosis assay market is growing rapidly due to innovations in biotechnology, rising healthcare needs, and the increasing focus on personalized medicine, especially in oncology and ...

A new study from scientists at the UCLA Health Jonsson Comprehensive Cancer Center helps explain why glioblastoma, one of the most aggressive forms of brain cancer, becomes resistant to treatment, and ...

Karyopharm Therapeutics Inc. (Nasdaq: KPTI ), a commercial-stage Pharmaceutical company pioneering novel cancer therapies, today announced abstracts detailing selinexor data have been selected to be ...

Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myelomaRecommendation based on IMROZ ...

Ascentage Pharma, a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies.

The company aims to supercharge antibody treatments using specially designed protein “cages” that multiply their effects, opening up new opportunities in drug development. The company was spun ...

Ueda is holding an expandable toy that he uses to demonstrate how the company’s computationally designed Antibody Cages work. (GeekWire Photo / Alan Boyle) Three weeks after University of ...

Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Aichi 465-8603, Japan Exploratory Research Center on Life and Living Systems (ExCELLS), National Institutes of Natural ...